SCHEMBL604198

SCHEMBL604198

OCc1ccc(F)c(Br)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
KDM4E B2RXH2 3/20 0.47
CYP4F2 P78329 1/20 0.46
CYP4A11 Q02928 1/20 0.46
KIF11 P52732 1/20 0.39
RXRA P19793 1/20 0.39
GRIN1 Q05586 1/20 0.39
GRIN2B Q13224 1/20 0.39
FAAH O00519 1/20 0.38
PARP1 P09874 2/20 0.38
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
TSHR P16473 2/20 0.36
ALDH1A1 P00352 1/20 0.36
IDO1 P14902 1/20 0.35
TDO2 P48775 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4599785 0.83 CYP1A2 (0.53) CYP1A2CYP2D6CYP2C9CYP2C19NPSR1
SCHEMBL29545673 0.82 CYP4F2 (0.42) CYP1A2CYP2D6CYP2C9CYP2C19NPSR1
SCHEMBL509144 0.82 CYP4F2 (0.42) CYP1A2CYP2D6CYP2C9CYP2C19NPSR1
SCHEMBL30531106 0.79 CYP1A2 (0.50) CYP1A2CYP2D6CYP2C9CYP2C19NPSR1
SCHEMBL25359980 0.79 CYP1A2 (0.50) CYP1A2CYP2D6CYP2C9CYP2C19NPSR1
SCHEMBL29418197 0.79 CYP1A2 (0.53) CYP1A2CYP2D6CYP2C9CYP2C19NPSR1
SCHEMBL11244115 0.79 KDM4E (0.49) CYP1A2CYP2D6CYP2C9CYP2C19NPSR1
SCHEMBL333551 0.79 CYP1A2 (0.53) CYP1A2CYP2D6CYP2C9CYP2C19NPSR1
SCHEMBL93021 0.78 CYP4F2 (0.50) CYP4F2CYP4A11KIF11MAOAMAOB
SCHEMBL29875658 0.78 CA2 (0.38) CYP1A2CYP2D6CYP2C9CYP2C19NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118439937-A Synthetic method of 4-fluoro-3-phenoxybenzaldehyde serving as key intermediate of insect repellent 康龙化成(绍兴)药业有限公司 2024-08-06 CN claimed
EP-0024612-B1 NEW 4-FLUORO-3-PHENOXY-BENZYL-ETHERS, PROCESS FOR THEIR PREPARATION AND THEIR USE BAYER AG (DE) 1983-10-05 EP claimed
EP-0059365-A2 3-Bromo-4-fluoro-benzyl derivatives, and methods for their preparation BAYER AG (DE) 1982-09-08 EP claimed
US-4326087-A REACTING 3-BROMO-4-FLUORO-BENZYL ALCOHOL WITH A CHLORINATING OR BROMINATING AGENT OR 3-BROMO-4-FLUORO-BENZOYL FLUORIDE WITH A HYDRIDE BAYER AKTIENGESELLSCHAFT (DE) 1982-04-20 US claimed
EP-0048914-A1 Process for the preparation of 3-bromo-4-fluorobenzyl alcohol, intermediate products therefor, and process for the preparation of these intermediate products BAYER AG (DE) 1982-04-07 EP claimed
EP-0024612-A2 New 4-fluoro-3-phenoxy-benzyl-ethers, process for their preparation and their use BAYER AG (DE) 1981-03-11 EP claimed
US-20250197368-A1 2-OXO-DIHYDROQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS GABA TYPE A RECEPTOR MODULATORS DRAIG THERAPEUTICS LTD. (GB) 2025-06-19 US disclosed
CN-118439937-A Synthetic method of 4-fluoro-3-phenoxybenzaldehyde serving as key intermediate of insect repellent 康龙化成(绍兴)药业有限公司 2024-08-06 CN disclosed
EP-4228761-A1 2-OXO-DIHYDROQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS GABA TYPE A RECEPTOR MODULATORS University College Cardiff Consultants Limited (GB) 2023-08-23 EP disclosed
CN-116472042-A 2-oxo-dihydroquinoline-3-carboxamide derivatives as modulators of GABA A type receptors 加的夫大学学院咨询有限公司 2023-07-21 CN disclosed
US-11560389-B2 Heterocyclic inhibitors of monocarboxylate transporters UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2023-01-24 US disclosed
CN-110325531-B Benzenesulfonamides and their use as therapeutic agents 泽农医药公司 2022-05-27 CN disclosed
WO-2022079432-A1 2-OXO-DIHYDROQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS GABA TYPE A RECEPTOR MODULATORS UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2022-04-21 WO disclosed
EP-0059365-A2 3-Bromo-4-fluoro-benzyl derivatives, and methods for their preparation BAYER AG (DE) 1982-09-08 EP disclosed
US-4326087-A REACTING 3-BROMO-4-FLUORO-BENZYL ALCOHOL WITH A CHLORINATING OR BROMINATING AGENT OR 3-BROMO-4-FLUORO-BENZOYL FLUORIDE WITH A HYDRIDE BAYER AKTIENGESELLSCHAFT (DE) 1982-04-20 US disclosed
EP-0048914-A1 Process for the preparation of 3-bromo-4-fluorobenzyl alcohol, intermediate products therefor, and process for the preparation of these intermediate products BAYER AG (DE) 1982-04-07 EP disclosed
EP-0048914-A1 Process for the preparation of 3-bromo-4-fluorobenzyl alcohol, intermediate products therefor, and process for the preparation of these intermediate products BAYER AG (DE) 1982-04-07 EP disclosed
EP-0048914-A1 Process for the preparation of 3-bromo-4-fluorobenzyl alcohol, intermediate products therefor, and process for the preparation of these intermediate products BAYER AG (DE) 1982-04-07 EP disclosed
EP-0024612-A2 New 4-fluoro-3-phenoxy-benzyl-ethers, process for their preparation and their use BAYER AG (DE) 1981-03-11 EP disclosed
EP-0024624-A2 4-Fluoro-3-phenoxy-benzaldehyde acetals, process for their preparation and intermediate products therefor BAYER AG (DE) 1981-03-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11560389-B2 Heterocyclic inhibitors of monocarboxylate transporters SLC16A1, SLC16A3, SLC16A7 CYP1A2 1205/4885CYP2D6 1231/4885CYP2C9 1146/4885
US-20250197368-A1 2-OXO-DIHYDROQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS GABA TYPE A RECEPTOR MODULATORS GABRA2, GABRA3, GABRB2 CYP1A2 181/4885CYP2D6 618/4885CYP2C9 834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.